Navigation Links
Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
Date:12/14/2007

INDIANAPOLIS, Dec. 14 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that Robert Conley, M.D., will join Lilly in January, 2008, as a Distinguished Lilly Scholar focusing on schizophrenia and other psychotic illnesses.

"We are absolutely delighted to have Dr. Conley join our team here at Lilly," said Jack Harris, M.D., vice president, U.S. Medical Division. "Rob is a well-known thought leader, clinician and scientist who brings important experience to Lilly as we continue to realize our vision of serving the patient. His experience will allow him to play a key scientific leadership role in our relationships with the U.S. physician community as well as the broader clinical and scientific communities."

Conley joins Lilly from the University of Maryland in Baltimore, where he is professor of psychiatry and pharmacy science. His work there focused on developing better treatments for patients with schizophrenia and other psychotic illnesses. With his colleagues at the Maryland Psychiatric Research Center and the National Institute on Drug Abuse, he also helped improve treatment for patients with poorly responsive schizophrenia through increased understanding of the most effective and safest ways to use antipsychotics.

After receiving his bachelor's degree from the John Hopkins University, Conley earned his medical degree from the University of Maryland in Baltimore. He did post-graduate work at the Western Psychiatric Institute & Clinic at the University of Pittsburgh before joining the faculty at the University of Maryland in Baltimore. He is an accomplished author and serves on numerous national peer-review boards.

"I am very pleased that Rob has decided to join Lilly," said Alan Breier, M.D., vice president and Lilly's chief medical officer. "He is an internationally recognized leader in schizophrenia research and will bring great technical depth and disease state knowledge to our company. Our commitment to neuroscience is quite strong, and the addition of Rob only strengthens our expertise in this area."

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

C-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
2. Immunotec Inc. announces retirement of President & CEO C.H. (Chuck) Roberts
3. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
6. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
7. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
8. Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting
9. Amarin Signs Agreement to Acquire Ester Neurosciences
10. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
11. Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
Breaking Biology Technology:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
Breaking Biology News(10 mins):